To assess the in vivo potential of concurrent JAK2 and c-Myc inhibition in vivo, mice were transplanted with Eμ-Crlf2/Jak2R683G B-ALL cells and treated with 50 mg/kg JQ1 once per day and 90 mg/kg ruxolitinib twice per day alone or in combination. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.